Last update 21 Nov 2024

ALMB-0166

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
GJA1
Mechanism
GJA1 inhibitors(Gap junction alpha-1 protein inhibitors)
Therapeutic Areas
Nervous System DiseasesCardiovascular DiseasesOther Diseases+ [2]
Active Indication
acute spinal cord injurySpinal Cord InjuriesStroke+ [2]
Inactive Indication-
Originator Organization
Shanghai Enlemai Biotechnology Co., Ltd.
Active Organization
Alamab Therapeutics, Inc.Alamab Therapeutics, Inc.Shanghai Enlemai Biotechnology Co., Ltd.CSPC Megalith Biopharmaceutial Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with ALMB-0166
CTR20211655 / RecruitingPhase 1
评价ALMB-0166在急性脊髓损伤患者中的安全性、耐受性和药代动力学特征的多中心、随机、双盲、安慰剂对照的Ⅰ期临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of ALMB-0166 in patients with acute spinal cord injury
NCT05524103 / RecruitingPhase 1
A Phase Ⅰ, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury
ACTRN12619001689167 / CompletedPhase 1
A Phase 1 Single Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALMB-0166 Administered to Healthy Subjects
100 Clinical Results associated with ALMB-0166
Login to view more data
100 Translational Medicine associated with ALMB-0166
Login to view more data
100 Patents (Medical) associated with ALMB-0166
Login to view more data
100 Deals associated with ALMB-0166
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
acute spinal cord injuryPhase 2
US
Alamab Therapeutics, Inc.Alamab Therapeutics, Inc.
10 Aug 2022
Spinal Cord InjuriesPhase 2
CN
CSPC Megalith Biopharmaceutial Co., Ltd.
-
StrokePhase 2
CN
CSPC Megalith Biopharmaceutial Co., Ltd.
-
Ischemic strokeIND Approval
CN
Shanghai Enlemai Biotechnology Co., Ltd.
15 Nov 2023
OsteoarthritisIND Approval
CN
Shanghai Enlemai Biotechnology Co., Ltd.
29 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free